Transforming Cancer Drug Development Via Artificial Intelligence
Using a simulation-based drug discovery platform, Turbine is dramatically reshaping drug discovery and development, explains CEO and co-founder Szabolcs Nagy, a 2021 Rising Leader.
You may also be interested in...
Private Company Edition: Vertex Ventures (not Vertex Pharmaceuticals) closed its third fund, with $200m for life science and medical technologies, while Chugai’s $200m corporate VC fund will invest in drug discovery start-ups. Also, K36 closed a $70m series B round and Attovia launched with $60m.
Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.
With all of the advancements in the life sciences industry, there is one area that is still assessed the way it has been for 100 years, subjectively. Pain. Gilat Zuckerman-Stark’s vision to improve patient outcomes comes from combining patience, persistence, education and artificial intelligence.